An examination of social presence in an online learning environment.

The distance education literature is lacking studies investigating the construct of social presence, the value placed on it by online learners, and whether its existence in text-based environments is necessary for learning, satisfaction, and contributing to course retention. The purpose of this study was to explore learner perceptions and experiences of the learning process within the Web-based online learning medium in terms of social presence. More specifically, it examines the relationship among learners\u27 perceptions of social presence in asynchronous online courses and how it relates to satisfaction with learning, whether course activities perceived as having high levels of social presence also have high levels of satisfaction and quality of learning, and whether perceptions of social presence and satisfaction with learning affects their likelihood of enrolling in future online courses. The research design of this study utilized an online survey administered to 280 students enrolled in online courses of nine disciplines; both undergraduate- and graduate- level at a large urban university. Open-ended questions from the online survey were examined as well to help inform and support the findings from the quantitative data. Data were analyzed using correlations, ANOVAs, and hierarchical regression analysis. The findings demonstrated that students\u27 perceived social presence was statistically, significantly, and positively related to their overall perceived satisfaction with learning in online courses. Furthermore, students\u27 perceived social presence was statistically, significantly, and positively related to their perception of quality of and satisfaction with learning for each of the five course activities examined in this study. The hierarchical regression analysis suggested that perceived social presence contributed substantially more incremental variance to the decision to enroll again in an online course than the satisfaction with learning variable. Overall, the theoretical model including social presence and satisfaction with learning explained 18 percent of the variance in the dependent variable. The potential implications for theory and practice for online course designers and instructors are provided

Gene Flow Between Great Lakes Region Populations of the Canadian Tiger Swallowtail Butterfly, \u3ci\u3ePapilio Canadensis\u3c/i\u3e, Near the Hybrid Zone With \u3ci\u3eP. Glaucus\u3c/i\u3e (Lepidoptera: Papilionidae)

Papilio canadensis were sampled from three locations on either side of Lake Michigan to study gene flow near and through a butterfly hybrid zone. Allele frequencies at four polymorphic enzyme loci, as indicated by allozyme electrophoresis, were similar in all samples. Values for FST were close to zero, indicating that gene flow is high among these populations, even when separated by Lake Michigan. We developed a mitochondrial DNA marker with diagnostic differences between P. canadensis and its parapatric sister species Papilio glaucus, based on PCR-RFLP. P. glaucus haplotypes of this mtDNA marker and P. glaucus alleles of a diagnostic allozyme locus (PGD) were found in P. canadensis populations sampled in Michigan’s Lower Peninsula but not in the Upper Peninsula or Northern Minnesota. The presence of P. glaucus alleles in P. canadensis populations could be due to introgression through hybridization, or could be remnants of a P. glaucus population that was inundated by an influx of P. canadensis alleles

Developing a theory of nightclub location choice

Thesis (M.C.P.)--Massachusetts Institute of Technology, Dept. of Urban Studies and Planning, 2008.Includes bibliographical references (p. 73-77).This work is an investigation of the factors that influence where nightclubs locate within a city. Nightclubs, like other social spaces, provide important social and economic benefits in the urban environment. As amenities, they attract labor to cities, and as sites of social exchange, they provide space in which individuals can create the networks necessary for innovative industrial production, especially in the fine arts and other creative sectors. Nightclubs also appear to have a role in neighborhood upgrading or gentrification. Despite their importance, this is the first study on the factors that determine nightclub location choice. New York City and primarily Manhattan were chosen as sites for investigation because of the City's high number of nightclubs, and because of the regulatory as well as real estate pressures that are currently affecting the industry. A variety of sources, including personal interviews with nightclub owners and their employees, various government documents, as well as spatial and non-spatial databases, were consulted to formulate conclusions. As is the case with other forms of retail, nightclub owners are most concerned with patron accessibility and proximity to complimentary businesses when deciding where to locate their businesses. Other factors are also discussed, as is a theory of how super-regional nightclub clusters form. Not surprisingly, the author finds that nightclub location choice is highly constrained by the content, administration, and evolution of various city and state laws. Finally, recommendations designed to ease the regulatory burden on nightclubs while still controlling for nuisance concerns are presented for both government agencies and the industry.by Stephen J. Crim.M.C.P

Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis.

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) are at risk of exacerbations and pneumonia; how the risk factors interact is unclear. METHODS: This post-hoc, pooled analysis included studies of COPD patients treated with inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations and comparator arms of ICS, LABA, and/or placebo. Backward elimination via Cox's proportional hazards regression modelling evaluated which combination of risk factors best predicts time to first (a) pneumonia, and (b) moderate/severe COPD exacerbation. RESULTS: Five studies contributed: NCT01009463, NCT01017952, NCT00144911, NCT00115492, and NCT00268216. Low body mass index (BMI), exacerbation history, worsening lung function (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage), and ICS treatment were identified as factors increasing pneumonia risk. BMI was the only pneumonia risk factor influenced by ICS treatment, with ICS further increasing risk for those with BMI <25 kg/m2. The modelled probability of pneumonia varied between 3 and 12% during the first year. Higher exacerbation risk was associated with a history of exacerbations, poorer lung function (GOLD stage), female sex and absence of ICS treatment. The influence of the other exacerbation risk factors was not modified by ICS treatment. Modelled probabilities of an exacerbation varied between 31 and 82% during the first year. CONCLUSIONS: The probability of an exacerbation was considerably higher than for pneumonia. ICS reduced exacerbations but did not influence the effect of risks associated with prior exacerbation history, GOLD stage, or female sex. The only identified risk factor for ICS-induced pneumonia was BMI <25 kg/m2. Analyses of this type may help the development of COPD risk equations

Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial

Background: Fluticasone furoate/vilanterol (FF/VI) is a novel once-daily (OD) inhaled corticosteroid/long-acting beta(2) agonist combination in development for chronic obstructive pulmonary disease (COPD) and asthma. Trial design: A multicentre, randomised, double-blind, parallel-group, placebo-controlled study. Methods: Participants were patients with moderate-to-severe COPD treated with placebo or FF/VI 400/25 mu g OD for 4 weeks. Study objectives were to assess the safety and efficacy of FF/VI 400/25 mg OD administered for 4 weeks via a novel dry powder inhaler. Co-primary end points were change from baseline in weighted mean (wm) heart rate 0-4 h postdose at day 28 and the incidence of adverse events (AEs). Secondary end points included change from baseline in trough forced expiratory volume in one second (FEV1) (23-24 h postdose; day 29) and wm FEV1 (0-4 h postdose; day 28). Patients were randomised to receive FF/VI 400/25 mg or placebo in a 2: 1 ratio; all patients and investigators were blinded to active or placebo treatment. Results: 60 patients (mean age 64 years) were randomised (FF/VI: n=40; placebo: n=20), and all contributed data to the analysis. Mean screening post-bronchodilator FEV1 per cent predicted was comparable between groups (FF/VI: 58.5%; placebo: 60.1%). The wm heart rate 0-4 h postdose was similar between groups (difference: 0.6 beats per minute; 95% CI -3.9 to 5.1). More on-treatment AEs were reported in the FF/VI group (68%) compared with the placebo group (50%). The most common drug-related AEs in the FF/VI group were oral candidiasis (8%) and dysphonia (5%). There were no clinically relevant effects on laboratory values, including glucose and potassium, or on vital signs or ECGs/Holters. The FF/VI group had statistically greater improvements compared with placebo in trough FEV1 (mean difference 183 ml) and 0-4 h postdose wm FEV1 (mean difference 236 ml). Conclusion: FF/VI has a good safety and tolerability profile and improves lung function compared with placebo in patients with COPD. Trial registration number: clinical trials. gov-NCT00731822

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.

SummaryBackgroundOnce-daily combination treatment is an attractive maintenance therapy for COPD. However, the dose of inhaled corticosteroid to use in a once-daily combination is unknown. We compared two strengths of fluticasone furoate (FF) plus vilanterol (VI), the same strengths of the individual components, and placebo.MethodsMulticentre, randomised, 24-week, double-blind, placebo-controlled, parallel-group study in stable, moderate-to-severe COPD subjects (N = 1224). Subjects were randomised to FF/VI (200/25 μg; 100/25 μg), FF (200 μg; 100 μg), VI 25 μg, or placebo, once daily in the morning. Co-primary efficacy endpoints; 0–4 h weighted mean (wm) FEV1 on day 168, and change from baseline in trough (23–24 h post-dose) FEV1 on day 169. The primary safety objective was adverse events (AEs).ResultsThere was a statistically significant (p < 0.001) increase in wm FEV1 (209 ml) and trough FEV1 (131 ml) for FF/VI 200/25 μg vs. placebo; similar changes were seen for FF/VI 100/25 μg vs. placebo. Whereas the difference between FF/VI 200/25 μg and VI 25 μg in change from baseline trough FEV1 (32 ml) was not statistically significant (p = 0.224), the difference between FF/VI 200/25 μg and FF 200 μg for wm FEV1 (168 ml) was significantly different (p < 0.001). VI 25 μg significantly improved wm and trough FEV1 vs. placebo (209 ml and 131 ml, respectively). No increase was seen in on-treatment AEs or serious AEs (SAEs), with active therapy vs. placebo.ConclusionsFF/VI provides rapid and significant sustained improvement in FEV1 in subjects with moderate-to-severe COPD, which was not influenced by the dose of FF. These data suggest that FF/VI may offer clinical efficacy in COPD and warrants additional study.GSK study number: HZC112207.ClinicalTrials.gov: NCT01054885

Barley in Minnesota

12 pages; includes photographs. This archival publication may not reflect current scientific knowledge or recommendations. Current information available from the University of Minnesota Extension: https://www.extension.umn.edu

Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial

Background. Fluticasone furoate/vilanterol (FF/VI) is a novel once-daily (OD) inhaled corticosteroid/long-acting β2 agonist combination in development for chronic obstructive pulmonary disease (COPD) and asthma. Trial design. A multicentre, randomised, double-blind, parallel-group, placebo-controlled study. Methods. Participants were patients with moderate-to-severe COPD treated with placebo or FF/VI 400/25 μg OD for 4 weeks. Study objectives were to assess the safety and efficacy of FF/VI 400/25 μg OD administered for 4 weeks via a novel dry powder inhaler. Co-primary end points were change from baseline in weighted mean (wm) heart rate 0–4 h postdose at day 28 and the incidence of adverse events (AEs). Secondary end points included change from baseline in trough forced expiratory volume in one second (FEV1) (23–24 h postdose; day 29) and wm FEV1 (0–4 h postdose; day 28). Patients were randomised to receive FF/VI 400/25 μg or placebo in a 2:1 ratio; all patients and investigators were blinded to active or placebo treatment. Results. 60 patients (mean age 64 years) were randomised (FF/VI: n=40; placebo: n=20), and all contributed data to the analysis. Mean screening post-bronchodilator FEV1 per cent predicted was comparable between groups (FF/VI: 58.5%; placebo: 60.1%). The wm heart rate 0–4 h postdose was similar between groups (difference: 0.6 beats per minute; 95% CI −3.9 to 5.1). More on-treatment AEs were reported in the FF/VI group (68%) compared with the placebo group (50%). The most common drug-related AEs in the FF/VI group were oral candidiasis (8%) and dysphonia (5%). There were no clinically relevant effects on laboratory values, including glucose and potassium, or on vital signs or ECGs/Holters. The FF/VI group had statistically greater improvements compared with placebo in trough FEV1 (mean difference 183 ml) and 0–4 h postdose wm FEV1 (mean difference 236 ml). Conclusion. FF/VI has a good safety and tolerability profile and improves lung function compared with placebo in patients with COPD.publishedVersio